# **Resource Summary Report**

Generated by NIF on May 5, 2025

# **Cancer Dependency Map Portal**

RRID:SCR 017655

Type: Tool

## **Proper Citation**

Cancer Dependency Map Portal (RRID:SCR\_017655)

#### Resource Information

URL: https://depmap.org/portal/

**Proper Citation:** Cancer Dependency Map Portal (RRID:SCR\_017655)

**Description:** Portal for identifying genetic and pharmacologic dependencies and biomarkers that predicts them by providing access to datasets, visualizations, and analysis tools that are being used by Cancer Dependency Map Project at Broad Institute. Project to systematically identify genes and small molecule dependencies and to determine markers that predict sensitivity. All data generated by DepMap Project are available to public under CC BY 4.0 license on quarterly basis and pre-publication.

**Abbreviations:** DepMap Portal

**Synonyms:** Dependency Map Portal, Dependency Map portal, Cancer DepMap, Cancer Dependency Map Project

**Resource Type:** database, project portal, data or information resource, portal, catalog, data set

**Keywords:** Cancer, vulnerability, dataset, visualization, analysis, tool, catalog, biomarker, genetic, drug, sensitivity, tumor, model, FASEB list

**Funding:** 

Availability: Free, Available for download, Freely available

Resource Name: Cancer Dependency Map Portal

Resource ID: SCR\_017655

**Record Creation Time:** 20220129T080336+0000

**Record Last Update:** 20250505T054605+0000

## Ratings and Alerts

No rating or validation information has been found for Cancer Dependency Map Portal.

No alerts have been found for Cancer Dependency Map Portal.

#### Data and Source Information

Source: SciCrunch Registry

### **Usage and Citation Metrics**

We found 741 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF.

Belmontes B, et al. (2025) AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. Cancer discovery, 15(1), 139.

Whuk M, et al. (2025) Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells. ACS biomaterials science & engineering, 11(1), 280.

Pollin G, et al. (2025) Emergent properties of the lysine methylome reveal regulatory roles via protein interactions and histone mimicry. Epigenomics, 17(1), 5.

Tang L, et al. (2025) CXCL14 in prostate cancer: complex interactions in the tumor microenvironment and future prospects. Journal of translational medicine, 23(1), 9.

Christopher JA, et al. (2025) Global Proteomics Indicates Subcellular-Specific Anti-Ferroptotic Responses to Ionizing Radiation. Molecular & cellular proteomics: MCP, 24(1), 100888.

Zhao D, et al. (2025) Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening. Neoplasia (New York, N.Y.), 60, 101100.

Chen L, et al. (2025) Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events. Scientific reports, 15(1), 3048.

Geng J, et al. (2025) Network Mendelian randomisation analysis deciphers protein pathways

linking type 2 diabetes and gastrointestinal disease. Diabetes, obesity & metabolism, 27(2), 866.

Deng Y, et al. (2025) Enhancing staging in multiple myeloma using an m6A regulatory genepairing model. Clinical and experimental medicine, 25(1), 40.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Izaguirre G, et al. (2025) Dysregulation of FURIN and Other Proprotein Convertase Genes in the Progression from HPV Infection to Cancer. International journal of molecular sciences, 26(2).

Biar CG, et al. (2025) Curated loci prime editing (cliPE) for accessible multiplexed assays of variant effect (MAVEs). ArXiv.

Rambaldelli G, et al. (2025) From Flies to Humans: Conserved Roles of CEBPZ, NOC2L, and NOC3L in rRNA Processing and Tumorigenesis. bioRxiv: the preprint server for biology.

Lavallée É, et al. (2025) Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors. Life science alliance, 8(3).

Han S, et al. (2025) A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia (New York, N.Y.), 59, 101070.

Phillips AF, et al. (2025) Targeting chromosomally unstable tumors with a selective KIF18A inhibitor. Nature communications, 16(1), 307.

Shi J, et al. (2025) RPL36A activates ERK pathway and promotes colorectal cancer growth. Translational oncology, 51, 102170.

Vatapalli R, et al. (2025) Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities. Epigenomics, 17(1), 59.

Sun X, et al. (2025) Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer. Cancer research communications, 5(1), 119.

Lange M, et al. (2025) FSP1-mediated lipid droplet quality control prevents neutral lipid peroxidation and ferroptosis. bioRxiv: the preprint server for biology.